Home > Boards > US Listed > Biotechs > DermTech Inc (DMTK)

LA JOLLA, Calif.--(BUSINESS WIRE)--Jan. 16, 2020-- DermTech, Inc.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
greens12 Member Profile
 
Followed By 197
Posts 18,479
Boards Moderated 2
Alias Born 01/12/12
160x600 placeholder
DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021 Business Wire - 1/19/2021 4:30:00 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 1/19/2021 1:24:45 PM
DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Lar... Business Wire - 1/14/2021 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/13/2021 4:22:13 PM
DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cuta... Business Wire - 1/12/2021 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/11/2021 6:05:37 PM
DermTech Announces Closing of Public Offering of Common Stock & Full Exercise of Underwriters’ Option to Purchase Additiona... Business Wire - 1/11/2021 4:01:00 PM
DermTech Announces Pricing of Public Offering of Common Stock Business Wire - 1/7/2021
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 4:11:03 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/6/2021 4:07:36 PM
DermTech Announces Proposed Public Offering of Common Stock Business Wire - 1/6/2021 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 5:26:20 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 1/5/2021 4:37:54 PM
DermTech Announces Appointment of General Counsel Business Wire - 1/5/2021 4:30:00 PM
DermTech Receives Positive Medical Coverage by Geisinger Health System Business Wire - 12/29/2020 5:05:00 PM
DermTech Management to Present at the ICR Conference 2021 Business Wire - 12/28/2020 4:01:00 PM
DermTech Announces Topline Results of its TRUST Study: Results Confirm the High Negative Predictive Value of the PLA at 99% &... Business Wire - 12/17/2020 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/16/2020 4:40:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/16/2020 4:37:46 PM
DermTech’s Melanoma Test Included in Two Continuing Medical Education (“CME”) Sessions at 2020 Fall Clinical Virtual Gr... Business Wire - 12/11/2020 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2020 6:05:25 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2020 4:11:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2020 4:08:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2020 4:07:34 PM
DermTech Enters Into Agreement With Blue Shield of California Business Wire - 12/10/2020 4:01:00 PM
greens12   Thursday, 01/16/20 07:18:26 PM
Re: db7 post# 50
Post # of 95 
LA JOLLA, Calif.--(BUSINESS WIRE)--Jan. 16, 2020-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has contracted with a regional health plan to make DermTech’s gene expression based Pigmented Lesion Assay (“PLA”) for the early detection of melanoma available to the regional health plan’s commercial and Medicare Advantage membership. This is the first contract with this health plan that provides coverage for the PLA.

DermTech’s PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99% negative predictive value (“NPV”), meaning there is a less than 1% chance of the PLA missing a melanoma when administered properly.

“We are excited to announce that our test is now available to a segment of commercial and Medicare Advantage members. Our PLA test offers significant benefits in early melanoma detection and reduced biopsies of benign lesions while also reducing costs to the healthcare system,” said Dan Visage, Senior Vice President of Payor Access.
https://investors.dermtech.com/news-releases/news-release-details/dermtech-enters-commercial-and-medicare-advantage-payor-coverage

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences